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 ABSTRACT 
Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart-muscle 
disease primarily affecting the right ventricle (RV) and potentially causing sudden death in 
young people. The natural history of the disease is firstly characterized by a concealed form 
progressing over a biventricular involvement. Three different cases coming from the same 
family are presented together with a review of the literature. 
Methods and Results: Multi-parameter analysis including imaging and electrocardiographic 
analysis is presented since the first medical referral with follow-up ranging from 11 to 38 
years. Case 1 presented a typical RV involvement in agreement with the ECG pattern. Case 2 
presented a prevalent left ventricular involvement leading from the beginning to a pattern 
of dilated cardiomyopathy in agreement with his ECG evolution over the years. On the other 
side, Case 3 came to observation with a typical RV involvement (similar to Case 1) but with 
ECG evolution of typical left ventricle involvement (similar to Case 2). The genetic analysis 
showed a mutation in desmoglein-2 (DSG2) gene: p. Arg49His. Comparison between size and 
localization of ventricular dyskinesia at cardiovascular imaging and the surface 12 lead 
electrocardiography are proposed.    
Conclusions:  AVRC may lead to an extreme phenotypic variability in clinical manifestations 
even within patients coming from the same family in which AVRC is caused by the same 
genetic mutation. ECG progression over time reflects disease evolution and in particular 
cases may anticipate wall motion abnormalities by years.  
 
Abstract word count: 233. 
Keywords: arrhythmogenic right ventricular cardiomyopathy, cardiac magnetic resonance, 
electrocardiogram 
Abbreviation list: ARVC: Arrhythmogenic Right Ventricular Cardiomyopathy; ECG: 
electrocardiographic; CMR: cardiac magnetic resonance; HF: heart failure; EF ejection fraction; RV: 
right ventricle; LV left ventricle; VT: ventricular tachycardia; EPS: electrophysiologic study; PKP2: 
plakophilin-2; DSC2: desmocollin-2; DSP: desmoplakin; JUP: plakoglobin; RYR2: ryanodine receptor; 
SAECG: signal-averaged electrocardiogram; GLS: global longitudinal strain; LGE: late gadolinium 
enhancement. 
 
INTRODUCTION 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a rare inherited heart-muscle 
disease, characterized by myocardial atrophy, fibrofatty replacement, and ventricular 
arrhythmias, that primarily affects the right ventricle (RV)1. ARVC may lead with time to 
more diffuse RV and left ventricle (LV) involvement and may be difficult to distinguish 
clinically from dilated cardiomyopathy in the advanced stage2-4. Different genetic mutations 
and phenotypic expressions can lead to 3 distinct patterns of disease expression: classic, 
defined as isolated RV disease, or LV involvement in the presence of notable RV enlargement 
and/or dysfunction; left dominant with prominent LV manifestations in the setting of 
relatively mild right-sided disease; and biventricular, characterized by equal bilateral 
involvement4. The LV involvement increases incidence of clinical arrhythmic events and, 
compared with cases of isolated RV involvement, is associated with more severe 
cardiomegaly, inflammatory infiltrates and heart failure (HF)3-7. Natural history of disease is 
divided in four phases. Firstly a subclinical phase with concealed structural abnormalities and 
no symptoms reported; in this phase sudden death might be the first manifestation. 
Secondly an overt RV electrical disorder with ventricular arrhythmias originating from the 
RV. Thirdly RV failure due to progressive loss of myocardium with severe dilatation and 
systolic dysfunction and lastly an end stage biventricular involvement that can mimic dilated 
cardiomyopathy1. Latest diagnostic criteria8 have preferentially focused on RV analysis. 
Concealed phase is characterized by cellular injury that can trigger arrhythmic events. 
Electrocardiographic (ECG) changes and arrhythmias may develop before histological 
evidence of myocytes loss or clinical evidence of RV dysfunction and are early and sensitive 
markers of disease expression in ARVC9-11. The subclinical phase of disease may also be 
detected by imaging studies, as it has been shown for 2D echocardiography with strain 
analysis12. However the ECG progression with time in AVRC patients and its correlation with 
LV or RV involvement has seldom been reported.  
Aims of the present study were (1) to analyse the different phenotypic expression of ARVC 
and how the 12 lead ECG could predict LV or RV involvement in three AVRC patients of the 
same family and (2) to present a systematic review of the literature. 
METHODS 
Medical records of 3 adult cases, belonging to the same family, diagnosed with ARVC at the 
Division of Cardiology of “Città della Salute e della Scienza” Hospital, Turin, were analysed. 
Demographic data, presenting complaints, cardiac findings, electrocardiography, 
echocardiography, cardiac magnetic resonance (CMR) results and treatment data were 
collected. Patients signed a written informed consent to proceed with data analysis. The 
genetic analysis evaluated 174 genes associated with cardiovascular disease using the 
“TruSight Cardio Sequencing Kit”; whereupon the genetic analysis focused on genes involved 
directly on ARVC, in particular: plakophilin-2 (PKP2), desmocollin-2 (DSC2), desmoplakin 
(DSP), plakoglobin (JUP), TMEM43-encoding transmembrane protein 43, ryanodine receptor 
2 (RYR2). 
RESULTS 
We identified 3 cases of ARVC (3 adult males), from the same family with different 
phenotypic expression of the disease. None of the patients ever performed intensive 
physical activity and after the diagnosis they were advised to avoid moderate to intensive 
physical exercise. There was no difference in life style and cardiovascular profile risk among 
the three cases. In each patient epicardial coronary artery disease was ruled out by coronary 
angiography and CMR did not reveal any sign of different cardiomyopathy or myocarditis. 
First and second-degree relatives of these patients underwent ECG, signal-averaged 
electrocardiogram (SAECG), echocardiogram and CMR to exclude ARVC (Figure 1). Two 
sisters of Case 1 and 2 died at the age of 79 and 65 after acute ischemic stroke before 
performing a complete clinical evaluation; the ECGs didn’t show any sign of ARVC. Among 
the family members who completed the evaluation none, excluding our three index cases, 
satisfied diagnostic criteria for AVRC (Figure 1).   
 Case 1 
This is a 67-years-old male firstly referred to medical care in 1978 at the age of 29 with a 
history of dyspnea. ECG revealed negative T wave in V1-V4 precordial leads. Transthoracic 
echocardiography showed a LV EF of 53% and reduced contractility and dilatation of RV. 
From 1983 he experienced palpitations with demonstration of sporadic ventricular ectopy 
on Holter-ECG analysis. In 1985 he presented with ventricular tachycardia (VT) with LBBB 
morphology, heart rate 200 bpm. LV angiography showed a preserved ejection fraction and 
RV angiography revealed a peri-annular diaphragmatic aneurism; myocardial biopsy showed 
monocytes infiltration and thickened endocardium. On the basis of clinical history, ECG  and 
RV angiography, AVRC was diagnosed and beta blockers therapy with Nadolol started. In 
1995 he experienced an ischaemic stroke, hence he started anticoagulation therapy with 
vitamin K antagonist. Because of symptomatic sustained palpitations, by 1996 nadolol was 
substituted with sotalol and the patient underwent 2 electrophysiologic studies (EPS) with 
induction and ablation of two different morphologies of VT coming from the RV. CMR 
showed dilated RV with accentuated trabecular pattern, diffuse fibrofatty infiltration of the 
RV free wall and aneurismatic dilatation of the RV outflow tract. SAECG showed 3 positive 
criteria out of 3.  
Looking at the ECG evolution during this 38 year follow up, a progressive RV involvement is 
evident, with new onset right bundle branch block and epsilon wave in the right precordial 
leads and rightward QRS axis deviation on surface ECG. (Figure 2a). On the other side ECG 
signs of LV involvement are limited to R wave amplitude reduction in left lateral precordial 
leads and in D1 and aVL. This suggested predominant RV involvement, also confirmed by the 
recently repeated CMR, which showed dilated RV with reduced contractility (EF 17%), 
significant trabeculation, small aneurisms of infundibular and inferior-basal wall and along 
acute marginal wall, with adipose infiltration; LV anterior-basal and apical walls were 
thinned and dyskinetic, with adipose infiltration, but preserved EF (Figure 3, Appendix video 
1). The last transthoracic echocardiogram (2015) showed not dilated LV, with EF of 51%, in 
presence of hypokinesia of posterior-lateral wall; RV appeared significantly dilated (TDD 50 
mm), with preserved longitudinal contractility (TAPSE 23 mm), but reduced global function 
(FSA 28%). The genetic analysis performed in 2016 showed a mutation in DSG2 gene: p. 
Arg49His. 
 
Case 2 
This 70-years-old male suffered from extrasystolic palpitations since he was 30. Frequent 
polymorphic ventricular ectopic beats were recorded on Holter monitoring, which were 
reduced by beta-blocker therapy with propranolol. He was referred in 1993 for ischemic 
stroke. The ECG (1995) at the age of 49 years showed negative T waves the precordial leads 
up to V6 (Figure 2b), with demonstration of hypokinesia of anterior and apical wall at 
transthoracic echocardiogram. The CMR (1996) revealed fibrofatty infiltration in the 
infundibulum of RV, consistent with the diagnosis of ARVC. By 2006 he developed significant 
changes on CMR with spread fibrofatty involvement of LV, in particular of inferior 
interventricular septum and posterior-lateral wall, with reduction of global contractility. On 
the other side RV showed minimal abnormalities. Thereafter he progressively reduced his 
exercise tolerance in parallel with a greater involvement of LV and the consequent decline of 
LV EF. In particular, in the last 10 years CMR assessments showed wide involvement of the 
inferior and lateral regions with severe reduction of ventricular contractility (EF 25%), 
progressive thinning of ventricular wall and systolic bulging (Figure 3, Appendix video 1). ECG 
evolution, reflecting the progressive involvement of LV, was characterized by appearance of 
Q waves in DI, aVL, V5-V6 together with R wave amplitude reduction in the same leads and 
progressive enlargement of epsilon waves in antero-lateral leads; signs of RV involvement 
were less evident (Figure 2b).  He also suffered 2 demonstrated episodes of paroxysmal 
atrial fibrillation (in 2008 and 2009). From 2016 functional class worsened (NYHA III-IV) and 
the patient suffered 2 episodes of syncope, the last with demonstration of sustained VT, 
which was treated with cardioversion; he subsequently underwent EPS with induction and 
ablation of VT coming from the RV; also, an implantable cardioverter defibrillator was 
positioned. Last CMR revealed akinetic and thinned inferior and lateral LV wall leading to a 
severe contractile dysfunction (EF 25%); RV also showed diffused fibro-fatty infiltration, 
multiple systolic bulgings, with severe EF reduction (EF 25%). The genetic analysis performed 
in 2016 showed a mutation in DSG2 gene: p. Arg49His. 
 
Case 3 
This 58-years-old male was referred in 1994 at the age of 38 due to the familiar history of 
ARVC (Case 1 and 2). The ECG showed possible epsilon wave in V1 and aVF. He performed 
CMR which showed slight dilatation of RV, with adipose infiltration of the apex and focal 
bulging of infundibular wall; LV was normal. SAECG showed 3 positive criteria out of 3. 
Considering familiar history, ECG, SAECG and CMR, he was diagnosed with ARVC and nadolol 
was started. In 2003 he underwent EPS, which resulted negative for VT induction. 
Subsequent CMRs in 2006 and 2012 showed a progression in RV involvement with adipose 
infiltration of anterior and infundibular wall, extension of bulging area to anterior, inferior 
and lateral wall, and reduction of RV EF to 40%. Despite imaging indicate a broad and 
apparently exclusive involvement of RV, the evolution of ECG in the last years shows a 
reduction of R waves amplitude in left precordial leads and presence of negative T waves up 
to V6, likewise the ECG evolution in Case 2 (Figure 2c). We were facing with contradictory 
findings: imaging studies suggested a prevalent RV involvement (similar to Case 1) while ECG 
evolution suggested an important LV involvement (similar to Case 2). After the ECG showed 
LV involvement we needed to wait approximately three years before an asymptomatic 
involvement of  the LV could be detected. In fact, the last echocardiogram (2016) showed LV 
wall motion abnormalities at global longitudinal strain (GLS) evaluation, located at medium-
apical inferior and infero-lateral wall of the LV, and also mechanical dispersion of time to 
peak negative longitudinal strain in both RV and LV segments (Figure 4); this was confirmed 
by CMR which showed late gadolinium enhancement (LGE) in the same areas (Figure 3).  The 
genetic analysis performed in 2016 showed a mutation in DSG2 gene: p. Arg49His. 
 
The presence of common diagnostic criteria and the description of indicators of LV 
involvement of all the three cases during the follow-up is presented in Appendix Table 1 and 
2.  
 
DISCUSSION 
ARVC is a cardiomyopathy characterized by myocardial atrophy, fibrofatty replacement, and 
ventricular arrhythmias that usually primarily affects the RV1. It was initially considered to be 
strictly confined to the RV, but there is now a growing evidence that the LV can progressively 
be involved, so that it may be difficult in the advanced stage to distinguish clinically from 
dilated cardiomyopathy2-5,7,13,14. LV involvement in ARVC has been increasingly described, 
with reported prevalence of 16% in the first studies15 increasing to 76-84% in last reports3-7. 
Lindstrom et al demonstrated, by myocardial perfusion scintigraphy and echocardiography, 
LV abnormalities in 93% of their ARVC patients16. What was initially known as an isolated RV 
disease has been more recently shown by CMR data and pathology studies to be a wider 
spectrum of diseases. As a consequence, cardiologists are now focusing on a biventricular 
view rather than only on a right one and a more comprehensive term of “arrhythmogenic 
cardiomyopathy” has been proposed17. Sen-Chowdhry et al described 3 distinct patterns of 
disease expression, determined by different genetic mutations and phenotypic expressions: 
“classic”, defined as isolated RV disease, or LV involvement in the presence of notable RV 
enlargement and/or dysfunction; “left dominant”, with prominent LV manifestations in the 
setting of relatively mild right-sided disease; and “biventricular”, characterized by equal 
bilateral involvement4.  LV involvement is age dependent3 and is associated with clinical 
arrhythmic events, more severe cardiomegaly, inflammatory infiltrates and HF3-7. 
McKenna et al. in 1994 developed for the first time diagnostic criteria based on medical 
history and on morphological, functional, and structural abnormalities18. These criteria 
focused on overt and severe disease, but lacked sensitivity for earlier forms. Moreover the 
possibility of LV involvement was admitted, but was not included in the diagnostic criteria. 
The sensitivity in early forms was improved with the 2010 diagnostic criteria8. Despite 
predominantly LV involving disease, with a particular ECG pattern (inferolateral T-wave 
changes, ventricular ectopy, or VT with right bundle-branch block morphology) and a 
particular imaging pattern (epicardial or mid-myocardial LGE by CMR) had been previously 
recognized 4,7,19,20, none of these criteria were included. The task force concluded that future 
revision of diagnostic criteria would have filled this gap including arrhythmias originating 
from LV, or imaging suggestive of LV fibro-fatty replacement, or loco-regional LV wall motion 
abnormalities as diagnostic features. 
Several ECG abnormalities have been shown to develop over time reflecting disease 
progression and involvement of new myocardial areas, as QRS enlargement and T wave 
inversion in the precordial leads and epsilon waves21,22. ECG changes and arrhythmias may 
develop before histological evidence of myocyte loss or clinical evidence of RV dysfunction 
and are early and sensitive markers of disease expression in ARVC9-11. Epsilon wave is a 
marker of ventricular delayed activation due to late electrical depolarization of myocytes in 
the context of fibro-fatty tissue substitution and has been correlated with progressive RV 
involvement and therefore with a poor outcome22-25. It represents a major diagnostic criteria 
in 2010 Task Force Criteria when visible in right precordial leads (V1-V3)8. Gallo et al found 
that this marker was associated with the occurrence of sudden cardiac death, HF-related 
death and heart transplant21; accordingly Shulin Wu et al reported the presence of epsilon 
waves in 80% of patients at high-risk of cardiac mortality (previous sustained VT and RV 
failure) and in 51% of low-risk patients, without reaching statistical significance (p=0.16)26. 
The three cases we presented showed epsilon waves on the right precordial leads, however 
Case 2 developed epsilon waves also in the left precordial leads and in DI-aVL (Figure 2b, 
Appendix Table 2), reflecting the extended LV involvement by the fibro-fatty tissue 
substitution. This ECG evolution is not usually described in LV dominant or biventricular 
forms: Sen-Chowdhry et al, in a cohort of 200 probands (82% with LV involvement), reported 
epsilon waves in lateral leads only in 2 patients4; other reports described epsilon wave in V1-
V3, and characteristic negative T wave in left precordial leads3,4,7,14,27-34. Epsilon wave 
detection in left precordial leads may be underestimated. On our opinion this should be 
included in future diagnostic criteria. 
Similarly to epsilon wave, T wave inversion in leads V4-V5-V6 and low QRS voltages could 
indicate progression over time, as reported by Gallo et al21. T-wave inversion beyond V3 are 
characteristic of subjects with more severe RV dilation and dysfunction33,35-37, whereas 
negative T wave in lateral and inferior leads represent a typical sign of LV involvement in 
biventricular and LV dominant forms3,4,7,14,27-32,34. Furthermore, the progressive loss of 
contractile tissue, together with scar substitution of myocytes and the dilatation of the 
ventricles are associated with R wave reduction and Q/QS wave in the left precordial leads32: 
this phenomenon is particularly evident in Case 2 and 3. Noteworthy, similar to what already 
described for the RV, an occult phase of electrical involvement preceding the manifest 
contractile dysfunction can be recognized also for arrhythmogenic cardiomyopathy with 
prevalent LV involvement. In this report  Case 3 showed ECG abnormalities typical of LV 
involvement before any imaging modality could detect them (Figure 2b e 2c, Appendix Table 
2).   
LV involvement can be detected by CMR and echocardiography with strain pattern analysis. 
The first plays a relevant role in the diagnostic process of suspected AVRC18.  Fibrous 
replacement of the LV  wall starts from the epicardial layer, this portion of the ventricular 
wall in poorly involved in the contraction process, then, fibro-fatty substitution of this 
portion do not lead to wall motion abnormalities detectable with traditional 
echocardiography. These injured areas can be easily detected with LGE at CMR7,38. Despite 
this, almost all studies in literature focused on the RV and only few assessed the LV 
involvement by CMR4,39,40. Revised 2010 diagnostic criteria for CMR are focused on RV and 
consider major criteria the presence of regional RV akinesia/dyskinesia/dyssychronous RV 
contraction and one of the following: dilatation of RV ≥110mL/m2 (or ≥100mL/m2 for 
female) or a reduced RV EF (≤40%); the presence of lower RV dilatation (100-110 ml/m2 for 
male, 90-100 ml/m2 for female) or RV dysfunction (40-45%) is considered a minor criteria; 
tissue characterization of ventricular wall is only based on histological criteria8. Furthermore, 
in case of LV involvement the presence of LGE is really suggestive, but this is not included in 
last diagnostic criteria8.  
Surface echocardiography represents a fundamental tool in patients with suspected AVRC. 
Myocardial deformation analysis performed by the recently available methods of bi-
dimensional strain analysis is emerging as a promising tool in numerous pathological 
conditions. Its application in the subclinical phase of disease is intriguing and already 
reported in AVRC patients41,42. In particular the evaluation of mechanical dispersion of 
ventricular segments is reported to improve the ability to identify high-risk patients43,44. Case 
3 of our series was referred to our center with no wall motion abnormalities of LV reported 
at trans-thoracic echocardiography, despite this, application of strain methods analysis 
detected subclinical abnormalities in LV inferior wall (in particular basal and medium 
portion) and confirmed a clear involvement of RV free wall (Figure 4). Furthermore strain 
analysis revealed RV and LV mechanical dispersion. The LV involvement was then confirmed 
by the last CMR which showed a LGE in the same portions.  
Molecular genetic analysis has provided considerable progress in understanding the 
pathophysiology of ARVC and many mutations have been identified in 8 genes. The majority 
of mutations are in 5 genes encoding proteins of the desmosome: JUP, PKP2, DSP, DSG2, 
DSC2; mutations in several non-desmosomal genes including PLN-encoding phospholamban 
and TMEM43-encoding transmembrane protein 43 have also been reported to cause 
ARVC45. Evidence for additional locus heterogeneity includes 4 loci for which no genes have 
yet been identified. The 3 Cases we presented had a mutation in DSG2 encoded p. Arg49His 
which is considered “pathogenetic” (1/12068 allele in controls on ExAC database). DSG2 is 
the fourth recognized desmosomal gene causing ARVC and approximately 10% of patients 
with ARVC have mutations in DSG246,47. Preliminary reports described an important, 
sometimes predominant, LV involvement with this mutation, with characteristic T wave 
inversion in inferior and left precordial leads and reduced R wave voltages in V5-V647-49; 
otherwise a recent genotype-phenotype correlation study in 577 subjects described a LV 
dysfunction in 13% of DSG2 mutation carriers (in contrast with 37% with DSC mutation, 40% 
with DSP mutation, and 67% with PLN mutation)45. The DSG2 mutation were also found in 
8% of sudden cardiac death victims in the absence of morphologic cardiac abnormalities at 
autopsy 50.  
Despite the same genotype, a clearly different phenotype is evident. Case 1 showed a clear 
RV involvement with typical ECG signs of RV involvement. Case 2 had ECG signs of a clear LV 
involvement, in particular the progressive evolution to a QS morphology in left precordial 
leads together with left epsilon wave appearance (rarely reported). Imaging analysis in this 
patient showed a clear biventricular involvement with biventricular reduced ejection 
fraction. Case 3 was referred to our center with imaging tests suggestive for only RV 
involvement, but ECG showed a progression to rS in left precordial leads suggestive for LV 
involvement. After many years in which the ECG evolution was not followed by LV 
involvement at imaging studies, a subclinical wall motion abnormality of the LV was detected 
at the strain analysis and confirmed by the CMR.  
Such a phenotype variability in disease expression in the same family is rarely reported49. 
ECG evolution could anticipates of years the future wall motion abnormalities onset, that, at 
the subclinical level, may be detected by strain echocardiographic analysis and contrast 
guided CMR.  
CONCLUSIONS  
ARVC represents an extremely heterogeneous disease in which not only RV is involved. We 
presented three cases of ARVC belonging to the same family but with different phenotypic 
expression, in particular in LV involvement.  In these cases ECG changes reflect the disease 
progression demonstrated by imaging and also anticipate of years the wall motion 
abnormalities onset.  
 
LIMITS 
Our study has the limitation of observational study with patients evaluated in a single high 
experienced centre by a restricted group of physicians. Further studies are required to 
evaluate the diagnostic and prognostic impact of epsilon wave detection in left lateral 
precordial leads in AVRC patients. Larger sample size studies are also required to evaluate 
reliability of GLS analysis at surface echocardiography in AVRC patients and also to validate 
that certain ECG changes could predict LV involvement.  
 
 
 
 
  
Figure Legends 
Figure 1. Family tree. 
Figure 2. ECG progression of the three cases from the diagnosis to the last control during 
follow-up. On the left are presented the peripheral leads, on the right the precordial leads.  
Figure 3. Comparison of ECG and CMR of the three cases at similar age. In Case 1 ECG shows 
a predominant RV involvement (right bundle branch block, epsilon wave in the right 
precordial leads, rightward QRS axis deviation), confirmed by CMR: RV with significant 
trabeculation, small aneurisms of infundibular and inferior-basal wall and along acute 
marginal wall, with adipose infiltration; LV with thinned and discinetic anterior-basal and 
apical walls, with adipose infiltration. On the contrary, in Case 2 the ECG indicates a 
predominant LV involvement (Q waves in DI, aVL, V5-V6, with reduced R wave amplitude in 
the same leads and epsilon waves in antero-lateral leads), with a wide non-ischemic LGE on 
the inferior and the lateral regions, severe reduction of ventricular contractility (EF 25%), 
thinned ventricular wall and systolic bulging on CMR exam. Case 3 at a similar age shows an 
evident RV involvement with  initial signs of LV involvement, both on the ECG (reduction of R 
waves amplitude in left precordial leads and negative T waves up to V6) and on the CMR 
(LGE areas at medium-apical inferior and infero-lateral wall of the LV). 
Figure 4. Determination of longitudinal strain in apical view of LV and RV of Case 3. a) Two 
chambers apical view of LV. b) Four chambers apical view with determination of RV free wall 
longitudinal strain. Both RV and LV shows reduced global LS and mechanical dispersion.   
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